News & Press Releases | Roivant
WEBJul 19, 2024 · Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study. Read the full article here. Roivant stock is nearing a breakout Tuesday after the biotech company announced positive results in an eye-disease study and a $1.5 billion share repurchase.
Roivant sells dermatology spinoff to Organon in deal worth $1.2 …
WEBSep 18, 2024 · Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion. Organon is buying ...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon …
WEBSep 18, 2024 · Psoriasis is a common chronic inflammatory skin disease affecting over 8 million Americans 20 years or older and 125 million people worldwide. Organon has agreed to acquire Dermavant for aggregate ...
Organon makes $1.2bn play for Roivant’s immuno-dermatology …
WEB6 days ago · In this article: Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the ...
Press Releases - Roivant Sciences Ltd.
WEBSep 18, 2024 · Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma …
Roche Completes Acquisition of Telavant from Roivant, Including …
WEBDec 14, 2023 · BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion.
Roche Completes Acquisition of Telavant from Roivant, Including …
WEBDec 14, 2023 · BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG;...
Roivant Reports Financial Results for the Second Quarter Ended ...
WEBSep 30, 2023 · Roivant owns approximately 55.2% of Immunovant as of November 3, 2023. Dermavant: For the second quarter ended September 30, 2023, Roivant reported VTAMA net product revenue of $18.4M, representing a 28% gross-to …
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to …
WEBSep 18, 2024 · Resize. By Colin Kellaher. Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on ...
Roivant and Pfizer Form New Vant Company Focused on …
WEBDec 1, 2022 · A new Vant or Roivant subsidiary has been created to develop and fund these programs. The Vant will be fully responsible for funding global development of RVT-3101 in UC and in additional inflammatory and fibrotic diseases and holds commercial rights in the US and Japan.
Skip to content